Physician profile
Scott Vanappledorn
NPI 1215923479
$616.64
in general payments reported to CMS, 2019-2025
14 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.25 · 2021: $98.86 · 2022: $154 · 2023: $70.31 · 2024: $111 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $108.49 | 2021-2025 | Lumenis Pulse 50h, Moses |
| Procept Biorobotics Corporation | $87.85 | 2022-2025 | Aquabeam System |
| 180 Medical, INC. | $57.61 | 2022-2024 | Speedicath |
| Sumitomo Pharma America, INC. | $55.52 | 2024 | Orgovyx |
| Progenics Pharmaceuticals, INC. | $53.58 | 2022-2023 | Pylarify |
| Coloplast Corp | $52.16 | 2021-2025 | |
| Tolmar Pharmaceuticals, INC. | $40.67 | 2021-2022 | |
| Myovant Sciences INC. | $34.40 | 2021 | |
| Janssen Biotech, INC. | $30.18 | 2022 | |
| Edap Technomed INC | $25.36 | 2023 | |
| Ethicon INC. | $20.83 | 2022 | |
| Laborie Medical Technologies Corp. | $18.58 | 2025 | |
| Olympus America INC. | $16.25 | 2019 | |
| Amgen INC. | $15.16 | 2023 | Xgeva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Vanappledorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.